# Inducible Clindamycin-ResistantStaphylococcus aureus Strains in Africa: A Systematic Review

Authors: Muluneh Assefa
Journal: International Journal of Microbiology
 (2022)

---

## Abstract

Introduction. Excessive use of clindamycin enhances the acquisition of inducible clindamycin-resistant S. aureus strains, which is a significant health problem in Africa. The main objective of this review study was to determine the prevalence of inducible clindamycin resistance and related genes among S. aureus isolates in Africa. Methods. A qualitative systematic review was conducted on inducible clindamycin resistance among S. aureus isolates in Africa using electronic databases such as Google Scholar and PubMed. Articles published in English before 2021 were selected, and relevant data were extracted, collected, and analyzed. Results. In our search, 22 articles met the eligibility criteria for this review study. Of 3064 total S. aureus isolates, 605 had iMLSB phenotype. The overall prevalence of inducible clindamycin resistance in S. aureus isolates was 19.8% with a range of 2.9% to 44.0%. A high number of iMLSB phenotypes were observed in MRSA isolates (3.6–77.8%) than MSSA (0–58.8%). The overall prevalence of the iMLSB phenotype in MRSA strains was 26.8% (279/1041). The maximum peak prevalence of inducible clindamycin resistance among S. aureus isolates recorded in the continent was 44.0% in Egypt, followed by 35.8% in Libya and 33.3% in Uganda in 2017, 2007, and 2013, respectively. The highest prevalence of iMLSB phenotype in MRSA strains was reported in Egypt, 77.8%, followed by Nigeria, 75.0%, and Libya, 66.2%. Among the recovered drug-resistance genes, ermA, ermC, and msrA genes were commonly detected in Egypt with 67.9%, 70.0%, and 70.0% prevalence, respectively. Conclusion. This review highlights a higher inducible resistance of S. aureus, including MRSA strains to clindamycin in the continent. Regular screening of these strains, wise use of clindamycin, and molecular detection and genotyping of resistant genes are urgent.


---

## Body

## 1. Introduction

Staphylococcus aureus is normally found in human skin and mucous membranes. It is a common human pathogen that causes skin and soft-tissue infections, abscesses, pneumonia, osteomyelitis, endocarditis, arthritis, and sepsis in both the community and hospital environment, and the spread of methicillin-resistant Staphylococcus aureus (MRSA) through the acquisition of highly transmissible mecA/mecC genes has made treatment difficult [1, 2].Even though the global average incidence of MRSA is 40.0%, reports from African countries reveal rates ranging from 12.0 to 80.0%, with some countries exceeding 82.0% [3, 4]. Antimicrobial resistance has become a severe health hazard worldwide, and its burden has increased in Africa because of a highly infectious disease burden, poor hygiene, lack of environmental sanitation, and poor infection control. The treatment of MRSA infections in African nations is problematic due to the lack of antibiotics with proven efficacy [5]. The rising prevalence of community-acquired MRSA has sparked interest in using macrolide-lincosamide-streptogramin (MLSB) antibiotics, particularly clindamycin to treat S. aureus-associated pneumonia and skin and soft-tissue infections [6].Clindamycin is the chosen antibiotic because of its superior pharmacokinetics, availability in intravenous and oral formulations with 90% oral bioavailability, low cost, strong tissue penetration, accumulation in deep abscesses, and capacity to inhibit toxin generation inS. aureus [7]. Excessive use of clindamycin, on the other hand, enhanced the acquisition of inducible resistance, leading to therapeutic failure [8]. The main mechanisms of resistance in the MLSB drugs include target site alteration, efflux pump expression, and mutation [9]. The MLSB phenotype can be either constitutive (cMLSB phenotype) in which rRNA methylase is always produced) or inducible (iMLSB phenotype) in which methylase is produced only when an inducing substance like erythromycin is present. During treatment, iMLSB phenotypes can be mutated into cMLSB phenotypes [10]. Owing to this, the Clinical and Laboratory Standards Institute (CLSI) recommends using the double-disk diffusion method (D-test) for detecting inducible resistance to clindamycin among Staphylococcus aureus isolates [11].In Africa,S. aureus is becoming increasingly resistant to clindamycin due to clinicians’ rash use of antibiotics without performing D-test and lack of laboratory facilities for molecular approaches such as polymerase chain reaction (PCR) based resistance gene detection. Although there has been published research on inducible clindamycin resistance, little is known about its dissemination and clinical significance in Africa, necessitating a compilation of data from the continent. To fill this gap, this systematic review provides an updated summary and valuable data. Therefore, this study mainly aimed to determine the prevalence of inducible clindamycin resistance and related resistance genes among S. aureus isolates in Africa.


## 2. Methods

### 2.1. Literature Search Strategy in Databases

A systematic literature search was performed on published articles for inducible clindamycin resistance amongS. aureus isolates in Africa with a study period before 2021 using electronic databases such as PubMed and Google Scholar. The following keywords were used with the help of Boolean operators: “inducible clindamycin resistance” OR “macrolide-lincosamide-streptogramin B resistance” OR “D-test” AND (“Staphylococcus aureus” OR “S. aureus” OR “methicillin-resistant Staphylococcus aureus” OR “methicillin-sensitive Staphylococcus aureus” OR MRSA OR MSSA) AND (Africa). The references of included articles were appropriately scanned to access related articles of interest. The literature search was not limited to a specific publication or year of study. In this review, we considered all studies that described inducible clindamycin resistance in S. aureus obtained from any type of human study participant in Africa. The procedure of eligible study selection is demonstrated in Figure 1.Figure 1
Flow diagram showing the procedure of eligible study selection to undergo review.


### 2.2. Study Selection and Eligibility Criteria

All studies from Africa reported the following information in the full-text selected:(I)
Articles performed D-test for detecting the iMLSB phenotype inS. aureus according to CLSI guideline(II)
All articles published with a study period until 2021(III)
Articles published and written in English(IV)
Articles with well-defined objectives and methodology(V)
Articles from a human source of specimen(VI)
Articles including data on the number ofS. aureus isolates and any source of specimen used(VII)
Studies which investigated antibiotic resistance genes using PCR were also summarizedArticles that lacked all or most of the above variables, such as abstract only, not in English, duplicate reports, ambiguous results, and articles with overlapping data, were excluded.


### 2.3. Assessment of the Study Validity

The validity of each study was illustrated by the use of the selection and eligibility criteria described above, thereby excluding studies that have unclear results, are unrepresentative of the human population, or studies with noncomparable data. Studies vary in specimen source, and the human study population was not excluded.


### 2.4. Data Extraction and Collection

Essential data were extracted from eligible studies using Excel spreadsheet format, and any discrepancies were handled by the author. The following information was extracted from the selected studies: the percentage of iMLSB phenotype detected, the number ofS. aureus isolates identified, the study period, the study population, geographic area where the study was conducted, the source of the specimen, the method of detection, the coexistence of antibiotic resistance genes, and the references were all considered.


### 2.5. Data Synthesis and Analysis

The data were synthesized qualitatively. Because of the relatively small number of studies used, inconsistencies between studies, and heterogeneity of the study populations between countries, we did not perform a quantitative synthesis. Data were summarized in the extraction table and analyzed manually. The overall prevalence of inducible clindamycin resistance inS. aureus or MRSA strains was calculated using the following formula:(1)overall prevalence=sum of the iMLSB phenotypestotal number ofS.aureus/MRSA∗100%.According to the United Nations list of 54 African countries, the map of Africa was created using the website (https://mapchart.net/). Finally, charts were created using the Excel 2019 software.


## 2.1. Literature Search Strategy in Databases

A systematic literature search was performed on published articles for inducible clindamycin resistance amongS. aureus isolates in Africa with a study period before 2021 using electronic databases such as PubMed and Google Scholar. The following keywords were used with the help of Boolean operators: “inducible clindamycin resistance” OR “macrolide-lincosamide-streptogramin B resistance” OR “D-test” AND (“Staphylococcus aureus” OR “S. aureus” OR “methicillin-resistant Staphylococcus aureus” OR “methicillin-sensitive Staphylococcus aureus” OR MRSA OR MSSA) AND (Africa). The references of included articles were appropriately scanned to access related articles of interest. The literature search was not limited to a specific publication or year of study. In this review, we considered all studies that described inducible clindamycin resistance in S. aureus obtained from any type of human study participant in Africa. The procedure of eligible study selection is demonstrated in Figure 1.Figure 1
Flow diagram showing the procedure of eligible study selection to undergo review.


## 2.2. Study Selection and Eligibility Criteria

All studies from Africa reported the following information in the full-text selected:(I)
Articles performed D-test for detecting the iMLSB phenotype inS. aureus according to CLSI guideline(II)
All articles published with a study period until 2021(III)
Articles published and written in English(IV)
Articles with well-defined objectives and methodology(V)
Articles from a human source of specimen(VI)
Articles including data on the number ofS. aureus isolates and any source of specimen used(VII)
Studies which investigated antibiotic resistance genes using PCR were also summarizedArticles that lacked all or most of the above variables, such as abstract only, not in English, duplicate reports, ambiguous results, and articles with overlapping data, were excluded.


## 2.3. Assessment of the Study Validity

The validity of each study was illustrated by the use of the selection and eligibility criteria described above, thereby excluding studies that have unclear results, are unrepresentative of the human population, or studies with noncomparable data. Studies vary in specimen source, and the human study population was not excluded.


## 2.4. Data Extraction and Collection

Essential data were extracted from eligible studies using Excel spreadsheet format, and any discrepancies were handled by the author. The following information was extracted from the selected studies: the percentage of iMLSB phenotype detected, the number ofS. aureus isolates identified, the study period, the study population, geographic area where the study was conducted, the source of the specimen, the method of detection, the coexistence of antibiotic resistance genes, and the references were all considered.


## 2.5. Data Synthesis and Analysis

The data were synthesized qualitatively. Because of the relatively small number of studies used, inconsistencies between studies, and heterogeneity of the study populations between countries, we did not perform a quantitative synthesis. Data were summarized in the extraction table and analyzed manually. The overall prevalence of inducible clindamycin resistance inS. aureus or MRSA strains was calculated using the following formula:(1)overall prevalence=sum of the iMLSB phenotypestotal number ofS.aureus/MRSA∗100%.According to the United Nations list of 54 African countries, the map of Africa was created using the website (https://mapchart.net/). Finally, charts were created using the Excel 2019 software.


## 3. Results

### 3.1. Literature Search

In electronic database searches, 465 articles were retrieved. After removing duplicates, 361 articles were avoided based on their titles and abstracts. The full-text articles of the remaining 104 articles were reviewed in detail for eligibility. Of these, 82 articles were discarded after the full-text had been reviewed for appropriate methodology, study population, the source of the specimens, clear result, and standard microbiological technique. Finally, 22 articles were included in the synthesis of the review (Figure1).


### 3.2. General Characteristics of the Studies Included in This Systematic Review

The main characteristics of the 22 studies from 8 African countries included in this systematic review have been summarized in Table1. All the studies used D-test for detecting inducible clindamycin resistance in S. aureus isolates, but some of them also used PCR for confirming the MLSB resistance genes. Studies used various specimens from human sources including swabs such as nasal, vaginal, cervical, urethral, wound, throat, ear, eye, and palm, respiratory specimens such as sputum, bronchoalveolar lavages, and tracheal aspirates, pus, urine, catheter, blood, semen, cerebrospinal fluid, pleural fluid, ascetic fluid, synovial fluid, and others. In this systematic review, most of the studies were conducted in clinical patients admitted to hospitals or outpatients, and the rest were conducted in healthy individuals with S. aureus carriers. Out of six studies that performed PCR for detecting MLSB resistance genes, 5 (83.3%) were conducted in Egypt and 1 (16.7%) was in Uganda. The detection rate of inducible clindamycin resistance in MRSA and MSSA was not reported in Ethiopian studies and a study from Uganda. Additionally, the prevalence of the iMLSB phenotype was relatively higher in children and burn patients (Table 1).Table 1
Characteristics of studies reporting inducible clindamycin resistance inS. aureus isolates.
ReferencesStudy periodCountryPopulationSpecimen sourceS. aureusDetection methodiMLSB (%)iMLSB in MRSA (%)iMLSB in MSSA (%)Resistance genes (%)[12]2007LibyaBurn patientsSwabs from wounds, urine, blood, and others120D-test35.843/65 (66.2)0—[13]2008TanzaniaSurgical ward patientsPus, wound swabs, and aspirates160D-test28.816/26 (61.5)30/134 (22.0)—[14]2009 to 2010SudanHealthcare workers and adult communityNasal swabs114D-test25.410/23 (43.5)19/91 (20.9)—[15]2010TanzaniaChildren under the age of fiveNasal swabs114D-test16.74/12 (33.3)15/102 (14.7)—[16]2012 to 2013NigeriaInpatient or outpatientVaginal, cervical, wound, ear, and eye swabs, urine, blood, semen, and others205D-test11.23/4 (75.0)20/34 (58.8)—[17]2012 to 2013UgandaInpatient or outpatientBlood, CSF, swabs of ear, vaginal, nasal, pus, throat, urethral, urine, and wound300D-test and PCR33.3NANAermB (7.7), ermC (32.7), and msrA (14.3) genes[18]2014 to 2015TanzaniaSurgery patients and HCWsNasal and wound swabs189D-test19.66/10 (60.0)31/179 (17.3)—[19]2015TanzaniaInpatientsNasal swabs89D-test21.37/22 (31.8)12/67 (17.9)—[20]2015 to 2016NigeriaPoultry workersSwabs from palm186D-test17.713/31 (41.9)20/155 (12.9)—[21]2016EgyptChildrenPus, wound and eye swabs, blood, urine, catheter, respiratory sample, ear discharge, and others230D-test and PCR12.215/66 (22.7)13/165 (7.9)ermA (67.9), ermB (3.6), ermC (12.3), and both ermA and ermC (3.6) genes[22]2016 to 2017EgyptChildrenBlood, wound swab, and bronchoalveolar lavage107D-test and PCR44.027/65 (41.5)20/42 (47.6)ermA (29.0), ermC (18.7, ermB (4.6), both ermA and ermC (1.0), and ermA, ermB, and ermC (3.7)[23]2016 to 2018NigeriaInpatients or outpatientsWound and abscess, blood, urine, ear, nasal, vaginal, and urethral swabs265D-test12.129/164 (17.7)3/100 (3.0)—[24]2017Côte d’IvoireInpatients or outpatientsPus, blood, pleural fluid, sputum, wound, and urine35D-test2.91/28 (3.6)0—[25]2017EgyptInpatients or outpatientsEndotracheal aspirates, sputum, blood, urine, and wound swabs210D-test and PCR10.018/195 (9.2)3/15 (20.0)ermB (20.0), erm C (70.0), msrA (70.0), mphC (40.0), and lnuA (20.0) genes[26]2017EthiopiaInpatients or outpatientsWound swabs79D-test24.116/65 (24.6)3/14 (21.4)—[27]2017 to 2018EgyptInpatients or outpatientsUrine, pus, wound, wound swab, blood, and aspirates100D-test10.09/70 (12.8)1/30 (3.3)—[28]2017 to 2018SudanInpatientsPostoperative wound swabs94D-test15.97/42 (16.7)8/52 (15.4)—[29]2017 to 2018EgyptCancer patients with febrile neutropeniaPus, throat swabs, blood, urine, and sputum179D-test and PCR25.135/45 (77.8)10/45 (22.2)ermE (33.3) ermC (15.6), and both ermC and ermE (51.0) genes[30]2018 to 2019EgyptInpatients or outpatientsPus, blood, tracheal aspirates, urine, ascetic and synovial fluid176D-test and PCR13.620/108 (18.5)4/68 (5.9)ermA (16.0), ermB (45.5), and ermC (50.0) genes[31]2019EthiopiaCancer patientsNasal swabs59D-test17.0%NANA—[32]2020EthiopiaPrisonersNasal swabs27D-test7.4%NANA—[33]2021EthiopiaAdults with CAPSputum26D-test7.7%NANA—iMLSB, inducible MLSB; MRSA, methicillin-resistantStaphylococcus aureus; MSSA, methicillin-sensitive Staphylococcus aureus, PCR, polymerase chain reaction; CAP, community-acquired pneumonia; HCWs, healthcare workers; CSF, cerebral spinal fluid; NA, not available.


## 3.1. Literature Search

In electronic database searches, 465 articles were retrieved. After removing duplicates, 361 articles were avoided based on their titles and abstracts. The full-text articles of the remaining 104 articles were reviewed in detail for eligibility. Of these, 82 articles were discarded after the full-text had been reviewed for appropriate methodology, study population, the source of the specimens, clear result, and standard microbiological technique. Finally, 22 articles were included in the synthesis of the review (Figure1).


## 3.2. General Characteristics of the Studies Included in This Systematic Review

The main characteristics of the 22 studies from 8 African countries included in this systematic review have been summarized in Table1. All the studies used D-test for detecting inducible clindamycin resistance in S. aureus isolates, but some of them also used PCR for confirming the MLSB resistance genes. Studies used various specimens from human sources including swabs such as nasal, vaginal, cervical, urethral, wound, throat, ear, eye, and palm, respiratory specimens such as sputum, bronchoalveolar lavages, and tracheal aspirates, pus, urine, catheter, blood, semen, cerebrospinal fluid, pleural fluid, ascetic fluid, synovial fluid, and others. In this systematic review, most of the studies were conducted in clinical patients admitted to hospitals or outpatients, and the rest were conducted in healthy individuals with S. aureus carriers. Out of six studies that performed PCR for detecting MLSB resistance genes, 5 (83.3%) were conducted in Egypt and 1 (16.7%) was in Uganda. The detection rate of inducible clindamycin resistance in MRSA and MSSA was not reported in Ethiopian studies and a study from Uganda. Additionally, the prevalence of the iMLSB phenotype was relatively higher in children and burn patients (Table 1).Table 1
Characteristics of studies reporting inducible clindamycin resistance inS. aureus isolates.
ReferencesStudy periodCountryPopulationSpecimen sourceS. aureusDetection methodiMLSB (%)iMLSB in MRSA (%)iMLSB in MSSA (%)Resistance genes (%)[12]2007LibyaBurn patientsSwabs from wounds, urine, blood, and others120D-test35.843/65 (66.2)0—[13]2008TanzaniaSurgical ward patientsPus, wound swabs, and aspirates160D-test28.816/26 (61.5)30/134 (22.0)—[14]2009 to 2010SudanHealthcare workers and adult communityNasal swabs114D-test25.410/23 (43.5)19/91 (20.9)—[15]2010TanzaniaChildren under the age of fiveNasal swabs114D-test16.74/12 (33.3)15/102 (14.7)—[16]2012 to 2013NigeriaInpatient or outpatientVaginal, cervical, wound, ear, and eye swabs, urine, blood, semen, and others205D-test11.23/4 (75.0)20/34 (58.8)—[17]2012 to 2013UgandaInpatient or outpatientBlood, CSF, swabs of ear, vaginal, nasal, pus, throat, urethral, urine, and wound300D-test and PCR33.3NANAermB (7.7), ermC (32.7), and msrA (14.3) genes[18]2014 to 2015TanzaniaSurgery patients and HCWsNasal and wound swabs189D-test19.66/10 (60.0)31/179 (17.3)—[19]2015TanzaniaInpatientsNasal swabs89D-test21.37/22 (31.8)12/67 (17.9)—[20]2015 to 2016NigeriaPoultry workersSwabs from palm186D-test17.713/31 (41.9)20/155 (12.9)—[21]2016EgyptChildrenPus, wound and eye swabs, blood, urine, catheter, respiratory sample, ear discharge, and others230D-test and PCR12.215/66 (22.7)13/165 (7.9)ermA (67.9), ermB (3.6), ermC (12.3), and both ermA and ermC (3.6) genes[22]2016 to 2017EgyptChildrenBlood, wound swab, and bronchoalveolar lavage107D-test and PCR44.027/65 (41.5)20/42 (47.6)ermA (29.0), ermC (18.7, ermB (4.6), both ermA and ermC (1.0), and ermA, ermB, and ermC (3.7)[23]2016 to 2018NigeriaInpatients or outpatientsWound and abscess, blood, urine, ear, nasal, vaginal, and urethral swabs265D-test12.129/164 (17.7)3/100 (3.0)—[24]2017Côte d’IvoireInpatients or outpatientsPus, blood, pleural fluid, sputum, wound, and urine35D-test2.91/28 (3.6)0—[25]2017EgyptInpatients or outpatientsEndotracheal aspirates, sputum, blood, urine, and wound swabs210D-test and PCR10.018/195 (9.2)3/15 (20.0)ermB (20.0), erm C (70.0), msrA (70.0), mphC (40.0), and lnuA (20.0) genes[26]2017EthiopiaInpatients or outpatientsWound swabs79D-test24.116/65 (24.6)3/14 (21.4)—[27]2017 to 2018EgyptInpatients or outpatientsUrine, pus, wound, wound swab, blood, and aspirates100D-test10.09/70 (12.8)1/30 (3.3)—[28]2017 to 2018SudanInpatientsPostoperative wound swabs94D-test15.97/42 (16.7)8/52 (15.4)—[29]2017 to 2018EgyptCancer patients with febrile neutropeniaPus, throat swabs, blood, urine, and sputum179D-test and PCR25.135/45 (77.8)10/45 (22.2)ermE (33.3) ermC (15.6), and both ermC and ermE (51.0) genes[30]2018 to 2019EgyptInpatients or outpatientsPus, blood, tracheal aspirates, urine, ascetic and synovial fluid176D-test and PCR13.620/108 (18.5)4/68 (5.9)ermA (16.0), ermB (45.5), and ermC (50.0) genes[31]2019EthiopiaCancer patientsNasal swabs59D-test17.0%NANA—[32]2020EthiopiaPrisonersNasal swabs27D-test7.4%NANA—[33]2021EthiopiaAdults with CAPSputum26D-test7.7%NANA—iMLSB, inducible MLSB; MRSA, methicillin-resistantStaphylococcus aureus; MSSA, methicillin-sensitive Staphylococcus aureus, PCR, polymerase chain reaction; CAP, community-acquired pneumonia; HCWs, healthcare workers; CSF, cerebral spinal fluid; NA, not available.


## 4. The Geographic Area of Studies Reported Inducible Clindamycin-ResistantS. aureus in Africa

The incidence of inducible clindamycin resistance inS. aureus isolates was reported in eight countries (Libya, Egypt, Tanzania, Ethiopia, Nigeria, Sudan, Uganda, and Côte d’Ivoire) in three geographic regions of Africa such as eastern (9 studies), northern (8 studies), and western (5 studies) regions based on United Nations classification (Figure 2). Most of the studies reporting inducible clindamycin resistance in S. aureus were conducted in Egypt (75%, 6/8), followed by Tanzania (50%, 4/8), Ethiopia (50%, 4/8), Nigeria (50%, 4/8), Libya, Sudan, Uganda, and Côte d’Ivoire (12.5%, 1/8) each (Figure 2).Figure 2
Map of Africa showing number of articles from eight countries (Libya, Egypt, Tanzania, Ethiopia, Nigeria, Sudan, Uganda, and Côte d’Ivoire) which reported inducible clindamycin-resistantS aureus (drawn from https://mapchart.net/africa.html).


### 4.1. The Prevalence of Inducible Clindamycin Resistance amongS. aureus Isolates

In our review, we assessed the overall prevalence of inducible clindamycin resistance amongS. aureus isolates by adding all iMLSB phenotypes and dividing it by the total number of S. aureus isolates. The total number of S. aureus isolates in the review was found to be 3064. Among the total S. aureus isolates, 605 had an iMLSB phenotype. Thus, the overall prevalence of inducible clindamycin resistance in this review was found to be 19.8%. Similarly, the overall prevalence of the iMLSB phenotype in MRSA was calculated by adding all the number of iMLSB phenotypes and dividing it by the total number of MRSA isolates, which was 26.8% (279/1041). Studies were conducted between 2007 and 2021 from different areas of the country [12–33].The prevalence of inducible clindamycin resistance amongS. aureus isolates varies from place to place due to the difference in local clindamycin resistance. Inducible clindamycin resistance was first reported in 2007 in Libya among burn patients [12]. The prevalence range of inducible clindamycin resistance among the S. aureus isolates was 2.9–44% [12–33] (Figure 3). The highest peak prevalence of inducible clindamycin resistance among S. aureus isolates documented on the continent was 44.0% in 2017 in Egypt [21] and the minimum prevalence was 2.9% from Côte d’Ivoire [24]. In 2007 and 2013, respectively, the second (35.8%) [12] and third (33.3%) [17] highest peaks of inducible clindamycin resistance prevalence were reported. Despite a 33.3% record of inducible clindamycin resistance in 2013, there has been a progressive drop in the prevalence of inducible clindamycin resistance since 2007 [17]. A similar 10.0% prevalence was observed in Egypt during 2017 and 2018 [23, 27]. Generally, there were heterogeneous distribution and prevalence rate of inducible clindamycin resistance among S. aureus isolates in Africa according to the reviewed studies (Figure 3).Figure 3
The trend of inducible clindamycin-resistantS. aureus in Africa from 2007 to 2021.A high number of iMLSB phenotypes were observed in MRSA isolates, ranging from 3.6 to 77.8% than MSSA, which was within a range of 0–58.8% [12–16, 18–30] (Table 1). The highest prevalence of iMLSB phenotype among MRSA strains was reported in Egypt, 77.8% [29], followed by Nigeria, 75.0% [16]; Libya, 66.2% [12]; and Tanzania (61.5% [13]; 60.0% [18]). The lowest prevalence of the iMLSB phenotypes in MRSA strains was demonstrated in Côte d’Ivoire, 3.9% [24] (Figure 4). A zero prevalence of the iMLSB phenotype among MSSA strains was observed in 2007 and 2017 in Libya [12] and Côte d’Ivoire [24], respectively (Table 1). Additionally, cMLSB phenotype was reported in MRSA and MSSA strains, ranging between 0–75.0% and 0–60.0%, respectively [12, 13, 15, 19–30] (S1).Figure 4
The prevalence of iMLSB phenotype in MRSA strains in African countries (ordered using study period: Libya (2007), Tanzania (2008 to 2015), Sudan (2009 to 2018), Nigeria (2012 to 2018), Egypt (2016 to 2019), Côte d’Ivoire (2017), and Ethiopia (2017)). Abbreviations: iMLSB, inducible macrolide-lincosamide-streptogramin B; MRSA, methicillin-resistantStaphylococcus aureus.


### 4.2. Resistance Genes Related to MLSB Resistance

Despite the lack of complete information on the resistance genes, investigations have shown that manyS. aureus isolates coproduced resistance genes such as erm (A, B, C, E) genes, msrA genes, mphC genes, and lnuA genes. Among the recovered erm genes in Egypt, the ermC gene was a highly detected resistance gene, at 70.0% [23], followed by the ermA gene, with a 67.9% detection rate [21]. The msrA gene was also detected among S. aureus isolates, with a 70.0% high detection rate in Egypt [23]. A study in Uganda also revealed ermC genes (32.7%) [17]. Additionally, the mphC genes (40.0%), and lnuA genes (20.0%) were also detected from a study in Egypt [25] (Table 1).


## 4.1. The Prevalence of Inducible Clindamycin Resistance amongS. aureus Isolates

In our review, we assessed the overall prevalence of inducible clindamycin resistance amongS. aureus isolates by adding all iMLSB phenotypes and dividing it by the total number of S. aureus isolates. The total number of S. aureus isolates in the review was found to be 3064. Among the total S. aureus isolates, 605 had an iMLSB phenotype. Thus, the overall prevalence of inducible clindamycin resistance in this review was found to be 19.8%. Similarly, the overall prevalence of the iMLSB phenotype in MRSA was calculated by adding all the number of iMLSB phenotypes and dividing it by the total number of MRSA isolates, which was 26.8% (279/1041). Studies were conducted between 2007 and 2021 from different areas of the country [12–33].The prevalence of inducible clindamycin resistance amongS. aureus isolates varies from place to place due to the difference in local clindamycin resistance. Inducible clindamycin resistance was first reported in 2007 in Libya among burn patients [12]. The prevalence range of inducible clindamycin resistance among the S. aureus isolates was 2.9–44% [12–33] (Figure 3). The highest peak prevalence of inducible clindamycin resistance among S. aureus isolates documented on the continent was 44.0% in 2017 in Egypt [21] and the minimum prevalence was 2.9% from Côte d’Ivoire [24]. In 2007 and 2013, respectively, the second (35.8%) [12] and third (33.3%) [17] highest peaks of inducible clindamycin resistance prevalence were reported. Despite a 33.3% record of inducible clindamycin resistance in 2013, there has been a progressive drop in the prevalence of inducible clindamycin resistance since 2007 [17]. A similar 10.0% prevalence was observed in Egypt during 2017 and 2018 [23, 27]. Generally, there were heterogeneous distribution and prevalence rate of inducible clindamycin resistance among S. aureus isolates in Africa according to the reviewed studies (Figure 3).Figure 3
The trend of inducible clindamycin-resistantS. aureus in Africa from 2007 to 2021.A high number of iMLSB phenotypes were observed in MRSA isolates, ranging from 3.6 to 77.8% than MSSA, which was within a range of 0–58.8% [12–16, 18–30] (Table 1). The highest prevalence of iMLSB phenotype among MRSA strains was reported in Egypt, 77.8% [29], followed by Nigeria, 75.0% [16]; Libya, 66.2% [12]; and Tanzania (61.5% [13]; 60.0% [18]). The lowest prevalence of the iMLSB phenotypes in MRSA strains was demonstrated in Côte d’Ivoire, 3.9% [24] (Figure 4). A zero prevalence of the iMLSB phenotype among MSSA strains was observed in 2007 and 2017 in Libya [12] and Côte d’Ivoire [24], respectively (Table 1). Additionally, cMLSB phenotype was reported in MRSA and MSSA strains, ranging between 0–75.0% and 0–60.0%, respectively [12, 13, 15, 19–30] (S1).Figure 4
The prevalence of iMLSB phenotype in MRSA strains in African countries (ordered using study period: Libya (2007), Tanzania (2008 to 2015), Sudan (2009 to 2018), Nigeria (2012 to 2018), Egypt (2016 to 2019), Côte d’Ivoire (2017), and Ethiopia (2017)). Abbreviations: iMLSB, inducible macrolide-lincosamide-streptogramin B; MRSA, methicillin-resistantStaphylococcus aureus.


## 4.2. Resistance Genes Related to MLSB Resistance

Despite the lack of complete information on the resistance genes, investigations have shown that manyS. aureus isolates coproduced resistance genes such as erm (A, B, C, E) genes, msrA genes, mphC genes, and lnuA genes. Among the recovered erm genes in Egypt, the ermC gene was a highly detected resistance gene, at 70.0% [23], followed by the ermA gene, with a 67.9% detection rate [21]. The msrA gene was also detected among S. aureus isolates, with a 70.0% high detection rate in Egypt [23]. A study in Uganda also revealed ermC genes (32.7%) [17]. Additionally, the mphC genes (40.0%), and lnuA genes (20.0%) were also detected from a study in Egypt [25] (Table 1).


## 5. Discussion

The phenotypic analysis of the inducible resistance inS. aureus to clindamycin was demonstrated through the D-test across African countries. In this review study, the prevalence of inducible clindamycin resistance among the S. aureus isolates was found to be 19.8%, ranging from 2.9 to 44.0% [12–33]. Various studies have reported a comparable proportion of inducible clindamycin resistance among S. aureus isolates obtained from human sources such as studies in Odisha state, eastern India, 22.0% [7]; Nepal, 23.4% [34]; Malaysia, 22.1% [35]; and Israel, 20.0% to 25.0% [36]. This finding is significantly higher than the findings of the iMLSB phenotype from the systematic review and meta-analysis in Iran with 10.4% overall prevalence [37]. In Indian studies, inducible clindamycin resistance rate was 5.2% in Kashmir valley [38], 7% in Assam [39], 15.2% in Chennai [40], 13.71% in the sub-Himalayan region [41], and 14.8% in central India [42]. In Nepal, lower inducible clindamycin resistance rate was indicated across different areas with a prevalence of 14.9% [43], 11.48% [8], 15.2% [44], and 12.1% [45]. While studies have also reported a high proportion of inducible clindamycin resistance as the prevalence in West Bengal, India, 41.3% [46]; Nepal (39.7% [47]; 34.8% [48]); Jordan, 76.7% [49]; and Tokyo, Japan, 91.0% [50]. The different iMLSB phenotypes observed in various studies are because of the variation in the study population, geographic region, the source of the specimen, methicillin susceptibility, usage of MLSB antibiotics in the community and hospital settings, and drug-resistant clones.The emergence of inducible clindamycin resistance was comparatively higher among the clinical MRSA isolates as up to 77.8% recovered from cancer patients with febrile neutropenia [29]. In this study, the overall prevalence of inducible clindamycin resistance in MRSA strains was 26.8%. Comparable findings were reported in Nepal, 24.5% [44], and India (28.0% [41]; 25.0% [42]). Studies in Nepal (34.3% [47]; 76.4% [34]); India, 37.5% [51]; Malaysia, 46.7% [35]; and Jordan, 76.7% [49] demonstrated higher prevalence. However, this finding is higher than a study conducted in India (7.5% [39]; 18.7% [52]). The cMLSB phenotype prevalence in MRSA strain (28.9%) was in agreement with the study conducted in India, 29.26% [41], higher than studies conducted in Nepal (5.7% [47]; 11.2% [44]), India (16.6% [51]; 16.9% [39]), and Malaysia, 11.1% [35], but lower than a study from India, 64.8% [42]. This shows that clindamycin treatment proved effective against MSSA infections, but it can lead to treatment failure in MRSA infections, and iMLSB phenotypes can be mutated into cMLSB phenotype.The most common mechanism for MLSB resistance inS. aureus is the target site modification of 23S ribosomal RNA mediated by erm genes and strains exhibiting the iMLSB phenotype having a high frequency of spontaneous constitutive resistance mutations. Regarding the genotypic confirmation of MLSB resistance genes, our findings demonstrated that erm (A, B, C, E) genes and msrA genes were commonly detected genes. This finding is supported by other studies [34, 49, 53–58]. This indicates that the high spread and transmission of these genes significantly contribute to the increasing acquiring clindamycin resistance in S. aureus strains. As a limitation, the inclusion of studies with lower sample size results in a bias in the finding. Most studies studied only the prevalence of inducible clindamycin resistance; only a few studies reported resistance genes.


## 6. Conclusion

The current review study demonstrated a high prevalence of inducible clindamycin resistanceS. aureus isolates with varying proportions throughout the country. A relatively higher number of iMLSB phenotypes was observed in MRSA than in MSSA isolates and a high figure was reported in Egypt, 77.8%, and Nigeria, 75.0%. Additionally, these strains are closely related to resistance genes such as the ermA, ermC, and msrA genes. Hence, there is an urgent need for ongoing studies to further assess iMLSB-positive S. aureus strains especially MRSA and in the revision of clindamycin prescription. Genotypic detection of resistance genes is mandatory to minimize treatment failure.



---

*Source: 1835603-2022-04-19.xml*